Abrocitinib is a selective inhibitor of Janus kinase 1 approved to treat moderate‐to‐severe atopic dermatitis (AD). Phase 3 clinical trials have demonstrated the efficacy and safety of abrocitinib; nevertheless, there is a need for real‐world patient data. This study aimed to assess the efficacy and safety of abrocitinib in patients with AD in the real‐world setting. In this prospective, observational, multicentre study, all patients with AD enrolled in the French registry Observatory of Chronic Inflammatory Skin Diseases (‘Observatoire Maladies Cutanées Chroniques Inflammatoires’; OMCCI) who received abrocitinib were included. Effectiveness was evaluated using outcome measures provided by clinicians and patients, including quality‐of‐life scores. Adverse events (AEs) were also assessed. Sixty‐five patients were included, 45 with 1 year of follow‐up. Abrocitinib treatment resulted in a significant decrease in disease severity at 12 months. After 1 year, median (interquartile range; IQR) Eczema Area and Severity Index Score decreased from 16.00 (9.10, 19.00) to 2.10 (0.80, 6.40), median (IQR) Dermatology Life Quality Index improved from 10.00 (6.00, 13.00) to 1.00 (0.00, 7.00), median (IQR) Mental Component Score and Physical Component Score increased from 48.14 (44.60, 56.82) to 57.21 (48.97, 60.12) and from 30.84 (28.13, 34.93) to 34.85 (30.74, 39.39), respectively, indicating improvement; all changes from baseline were significant ( p < 0.001). The most frequently reported AEs included 13 (23.2%) cases of acne and 11 (19.6%) cases of gastrointestinal symptoms. Eleven patients discontinued abrocitinib treatment due to ineffectiveness (8 17.8%) or AEs (3 6.7%). Abrocitinib can be an effective and safe treatment for patients with moderate‐to‐severe AD in daily clinical practice.
Cinotti et al. (Thu,) studied this question.